These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 27512657)

  • 1. Cell carriers for oncolytic viruses: current challenges and future directions.
    Roy DG; Bell JC
    Oncolytic Virother; 2013; 2():47-56. PubMed ID: 27512657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesenchymal stem cells as carriers for systemic delivery of oncolytic viruses.
    Hadryś A; Sochanik A; McFadden G; Jazowiecka-Rakus J
    Eur J Pharmacol; 2020 May; 874():172991. PubMed ID: 32044323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Directing systemic oncolytic viral delivery to tumors via carrier cells.
    Nakashima H; Kaur B; Chiocca EA
    Cytokine Growth Factor Rev; 2010; 21(2-3):119-26. PubMed ID: 20226717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering Oncolytic Coxsackievirus A21 with Small Transgenes and Enabling Cell-Mediated Virus Delivery by Integrating Viral cDNA into the Genome.
    Sam M; Selman M; Zhao W; Jung J; Willingham A; Phan U; Starling GC; Gao Q
    J Virol; 2023 May; 97(5):e0030923. PubMed ID: 37070982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune cells: more than simple carriers for systemic delivery of oncolytic viruses.
    Eisenstein S; Chen SH; Pan PY
    Oncolytic Virother; 2014; 3():83-91. PubMed ID: 25767789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth.
    Munguia A; Ota T; Miest T; Russell SJ
    Gene Ther; 2008 May; 15(10):797-806. PubMed ID: 18356812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity.
    Power AT; Wang J; Falls TJ; Paterson JM; Parato KA; Lichty BD; Stojdl DF; Forsyth PA; Atkins H; Bell JC
    Mol Ther; 2007 Jan; 15(1):123-30. PubMed ID: 17164783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achieving systemic delivery of oncolytic viruses.
    Hill C; Carlisle R
    Expert Opin Drug Deliv; 2019 Jun; 16(6):607-620. PubMed ID: 31144549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
    Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
    J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic viruses: do they have a role in anti-cancer therapy?
    Prestwich RJ; Errington F; Harrington KJ; Pandha HS; Selby P; Melcher A
    Clin Med Oncol; 2008; 2():83-96. PubMed ID: 21892269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing Oncolytic Viral Design to Enhance Antitumor Efficacy: Progress and Challenges.
    Chaurasiya S; Fong Y; Warner SG
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32604787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy.
    Iankov ID; Blechacz B; Liu C; Schmeckpeper JD; Tarara JE; Federspiel MJ; Caplice N; Russell SJ
    Mol Ther; 2007 Jan; 15(1):114-22. PubMed ID: 17164782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stem Cell-Based Cell Carrier for Targeted Oncolytic Virotherapy: Translational Opportunity and Open Questions.
    Kim J; Hall RR; Lesniak MS; Ahmed AU
    Viruses; 2015 Nov; 7(12):6200-17. PubMed ID: 26633462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin D3-inducible mesenchymal stem cell-based delivery of conditionally replicating adenoviruses effectively targets renal cell carcinoma and inhibits tumor growth.
    Hsiao WC; Sung SY; Liao CH; Wu HC; Hsieh CL
    Mol Pharm; 2012 May; 9(5):1396-408. PubMed ID: 22480282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The utility of cells as vehicles for oncolytic virus therapies.
    Russell SJ; Peng KW
    Curr Opin Mol Ther; 2008 Aug; 10(4):380-6. PubMed ID: 18683103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Employing RNA viruses to fight cancer: novel insights into oncolytic virotherapy.
    Masemann D; Boergeling Y; Ludwig S
    Biol Chem; 2017 Jul; 398(8):891-909. PubMed ID: 28441138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultrasound-mediated oncolytic virus delivery and uptake for increased therapeutic efficacy: state of art.
    Nande R; Howard CM; Claudio PP
    Oncolytic Virother; 2015; 4():193-205. PubMed ID: 27512682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Oncolytic virus therapy for malignant brain tumors].
    Ino Y; Todo T
    Brain Nerve; 2009 Jul; 61(7):815-22. PubMed ID: 19618859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic virus immunotherapy: future prospects for oncology.
    Raja J; Ludwig JM; Gettinger SN; Schalper KA; Kim HS
    J Immunother Cancer; 2018 Dec; 6(1):140. PubMed ID: 30514385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient delivery of oncolytic enterovirus by carrier cell line NK-92.
    Podshivalova ES; Semkina AS; Kravchenko DS; Frolova EI; Chumakov SP
    Mol Ther Oncolytics; 2021 Jun; 21():110-118. PubMed ID: 33981827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.